Diffuse large B-cell lymphoma, not otherwise specified

It is a cancer of B cells — the white blood cells that normally make antibodies — and it is the most common type of non-Hodgkin lymphoma, making up about 30% of newly diagnosed cases.

“Aggressive” describes how fast it grows, not how likely it is to be fatal. It is worth separating those two things immediately, because the aggressive lymphomas are the ones most often treated with cure as the intention. The slow-growing ones are frequently the harder ones to be rid of.

“Not otherwise specified” is the category a large B-cell lymphoma falls into once the specific named types have been ruled out. It is not a vaguer or lesser diagnosis — it is the main one.

There are related conditions that look similar under the microscope but behave and are treated differently: primary mediastinal large B-cell lymphoma, which affects younger people and grows as a chest mass, and primary CNS lymphoma, which is confined to the brain, spinal cord and eyes.

None of the sources we read identifies a cause an individual could have avoided. Nothing here supports a diet, stress, lifestyle or environmental explanation, and we are not going to imply one.

What is known is that risk rises with age. No causal mechanism is offered for that in these sources beyond the general accumulation of genetic changes over a lifetime.

The sources we read do not report on inheritance, family risk or contagion, so we cannot say anything useful about those here. That is a gap in what we could verify rather than a reassurance.

It usually shows up as one or more painless swellings — in the neck, armpit, groin or abdomen. Those are enlarged lymph nodes.

About a third of people also have what are called B symptoms: fever, drenching night sweats, and unexplained weight loss. The name is simply the letter used when recording the stage.

It can also involve organs outside the lymph nodes, most often in the digestive tract.

Because it grows fast, symptoms usually develop over weeks rather than months, and treatment tends to start soon after diagnosis. That speed is unsettling but it is not in itself a statement about outlook.

Stage IV is the largest single group at diagnosis in US data, at about 40%. That is worth knowing precisely because it should not be read as untreatable — advanced-stage disease here is curable in a substantial proportion of people.

First-line treatment is chemotherapy given together with an antibody drug, rituximab — a combination usually called R-CHOP, or a newer variant that swaps one drug for polatuzumab. Cure is the stated intent.

The NCI reports that among people with advanced-stage disease, 50% are cured with these regimens, and that localised disease can be cured with combined treatment or chemotherapy alone.

Practically, advanced-stage disease usually means six cycles at 21-day intervals; early-stage disease a shorter course, sometimes with radiotherapy. For most readers that is a horizon measured in months, which is worth saying, because a new diagnosis feels boundless.

If the lymphoma comes back, the path used to be salvage chemotherapy followed by an autologous transplant — the person’s own stem cells, collected in advance and returned after high-dose chemotherapy. CAR T-cell therapy has now moved into second line for people whose disease did not respond to first-line treatment or returned within twelve months.

CAR-T is worth being precise about, because it is routinely misunderstood: the patient’s own T cells are collected, genetically engineered in a laboratory over about three to five weeks, and given back. It is not a transplant and there is no match involved.

Diagnosis means a biopsy — a procedure to remove a sample of tissue, usually a swollen lymph node — and treatment usually begins soon afterwards, because the lymphoma grows quickly.

Treatment is a defined course rather than something open-ended, and that matters psychologically more than it sounds. Six cycles at three-week intervals has an end date on it.

The word people hear is remission, and it is worth knowing it is not the same word as cure. Complete remission means no detectable lymphoma. Many people reach it, and for many that turns out to be permanent — but the two words are not interchangeable and clinicians use them carefully.

For those whose lymphoma returns, the second stretch is harder and less predictable than the first, and the honest thing to know going in is that the plan may change partway through if the disease does not respond.

The transplant a reader with this lymphoma is most likely to encounter uses their own cells. A registry donor is not the usual missing piece here.

In the EBMT reporting region in 2023, of 3,117 first transplants recorded for large B-cell lymphoma, 2,838 were autologous — 91.1%. The remaining 279 used someone else’s cells.

A donor becomes relevant only on a narrow path: an allogeneic transplant in high-risk disease that has relapsed or not responded. Lymphoma Action describes it plainly as less common than the autologous kind, and that is the whole honest claim.

CAR-T does not change that, because CAR-T involves no donor at all. The cells are the patient’s own, engineered and returned.